- LOGIN
- MemberShip
- 2026-05-11 13:24:52
- Company
- Yuhan’s Q1 operating profit rose fourfold this year
- by Chon, Seung-Hyun Apr 27, 2023 05:43am
- Yuhan Corp showed improved performance in Q1 compared to the previous year. A large amount of revenue from contract development and manufacturing (CDMO) royalties flowed in from its subsidiary Ad Pharma. Yuhan Corp announced on the 26th that operating profit based on its consolidated financial statements in Q1 was KRW 22.6 billion, which is a 3.7-fold increase from the KRW 6.1 billion in the same period of the previous year. Sales were KRW 443 billion, up 7.8% from the previous year. Yuhan Corp Its royalty revenue has increased significantly from KRW 1.5 billion in Q1 last year to KRW 7.2 billion. Yuhan Corp has signed licensing-out deals for new drug technologies from 5 global pharmacuetical companies including Janssen Biotech, Gilead Bioscience, Boehringer Ingelheim, and Processa Pharmaceuticals. Other than Processa Pharmaceuticals which had paid its upfront payment with stock, the company is recognizing the upfront payment and milestone payments from the other 4 companies in installments. In Q1, CDMO royalties have come in from its subsidiary Ad Pharma. Ad Pharma is a company specializing in the development of incrementally modified drugs. Ad Pharma has recently developed a rosuvastatin+ezetimibe combination and obtained consignment approvals from Jeil Pharmaceutical and GC Pharm. The company had also acquired Ad Pharma, a company specializing in incrementally modified drugs, for KRW 3 billion in 2017 and invested an additional KRW 7 billion last year. As of the end of last year, Yuhan Corp.'s stake in Ad Pharma was 67.7%. Yuhan Corp’s flagship businesses, including prescription drugs and over-the-counter drugs, also performed well. Sales of Yuhan Corp’s prescriptions in Q1 had increased 8.0% YoY from KRW 261 billion. Its diabetes treatment Jardiance rose 63.6% YoY to KRW 17.9 billion, and its hyperlipidemia treatment rosuvamibe made KRW 16.2 billion, recording a 63.6% rise in sales. Its over-the-counter drug sales have also increased 6.2% from the previous year to record KRW 55 billion. Sales of its non-steroidal anti-inflammatory drug antiphlamine rose 28.5 % from KRW 6.1 billion last year to KRW 7.7 billion. Its overseas sales in Q1 had also increased 24.3% from the previous year to a record KRW 69.2 billion. Yuhan Corp purchases APIs medicines produced by Yuhan Chemical and exports them to multinational pharmaceutical companies.
- Company
- GSK, cash equivalents of 250,000 won
- by Jung, Sae-Im Apr 27, 2023 05:41am
- GSK Korea's cash flow is rapidly deteriorating. It has not been able to generate cash through operating activities for three consecutive years, so money is not circulating. Cash equivalents fell to 250,000 won. Short-term borrowings borrowed to raise operating funds exceeded 90 billion won. According to the Financial Supervisory Service on the 24th, as of the end of last year, GSK Korea's cash and cash equivalents were 250,000 won, a decrease of about 100% from the previous year (15.1 billion won). Cash and cash equivalents, which were 33.2 billion won in 2018, gradually decreased to 14.9 billion won in 2019 and 6.1 billion won in 2020, and then bottomed out in 5 years. The company's cash equivalents bottomed out because cash outflows from operating activities continued for the third consecutive year. GSK Korea's cash flow from operating activities turned to an outflow of 3.6 billion won in 2020, and the amount of outflow soared to 36.5 billion won in 2021. Last year, the situation worsened with an outflow of 80.6 billion won. Looking at last year's operating cash flow excluding interest and corporate tax, the increase in trade receivables and inventories had a negative impact last year. According to GSK Korea's 'change in assets and liabilities due to operating activities' account, there was no cash flow of 24.7 billion won due to an increase in trade receivables. Accounts receivable refers to the amount of money sold by a company on credit. If sales increase on the books due to selling goods, but actual cash does not come in due to credit transactions, it is marked with a minus sign (-). The larger the negative value, the greater the number of credit transactions without payment. Compared to the previous year (6.2 billion won), account receivables increased by 30 billion won. Inventories also increased by 22.1 billion won from the previous year. GSK Korea purchases finished products from the headquarters, stocks them up, and sells them in Korea. Last year, the company suffered a cash outflow of 37.9 billion won because it could not sell goods as much as its inventory increased. As the working capital burden increased, GSK Korea's trade receivables and other receivables (accounts receivable) reached 158.7 billion won at the end of last year based on book value. This is a 19% increase over the previous year. During the same period, inventory increased by 70% from 77.7 billion won to 132.3 billion won. Companies running out of cash are raising operating funds with short-term borrowings that must be repaid within one year. GSK Korea, which borrowed 50 billion won in 2021, borrowed an additional 41.5 billion won last year. It also carried out a paid-in capital increase of 28.2 billion won. GSK headquarters and affiliate Stiefel participated in the paid-in capital increase. In particular, while new short-term borrowings have soared to 91.5 billion won in the last two years, liquidity concerns have grown as the cash equivalents currently held are only 250,000 won. Currently, short-term borrowings amount to 380,000 times cash equivalents. Trade and other debt liabilities to be paid within one year were also tallied at 39.3 billion won. To make matters worse, sales also declined last year due to the absence of new products and the suspension of vaccine supply. As the cost of sales increased, the operating profit also turned to the red. Last year, sales decreased by 9.4% from the previous year (304.4 billion won), and operating profit turned into a loss of -6.1 billion won. GSK Korea is trying to turn things around this year with Shingrix, a new shingles vaccine. Although Shingrix is more expensive than existing vaccines, it has changed the game in the global market with its overwhelmingly high preventive effect. Shingrix, which was officially released in Korea in December last year, is being sold in earnest in hospitals and clinics this year.
- Company
- GSK launches 90 cap pkg of Duodart for prostatic hyperplasia
- by Jung, Sae-Im Apr 27, 2023 05:40am
- GSK Korea (Robert Kempton, CEO of Korean corporation) announced on the 24th that it will release a 90-capsule large-capacity package of Duodart, a treatment for prostatic hyperplasia. With this release, one package can be taken for three months. The recommended dosage of Duodart is 1 capsule once daily. The Duodart 90-capsule package was sequentially supplied to wholesalers nationwide starting this month. Duodart is a 5α-reductase inhibitor (Dutasteride) + α-blocker (Tamsulosin hydrochloride) fixed-dose combination drug that was first released in Korea. The two ingredients are contained in one capsule to improve symptoms quickly and reduce the long-term risk of disease progression. It can be expected to improve medication compliance, such as minimizing the frequency of drug use, reducing the possibility of patient omissions, and simplifying treatment schedules. With the launch of this large-capacity package, GSK Korea plans to continue its efforts to improve medication compliance, which is inevitable in the treatment of benign prostatic hyperplasia. Prostatic hyperplasia is a chronic disease whose prevalence increases with age, and it is known that elderly patients are at high risk of taking multiple drugs that require attention. Multidrug use can lead to non-compliance with medications, and low medication compliance in patients with BPH has a high risk of complications such as acute urinary retention, renal failure, neurogenic bladder, BPH-related surgery, urinary tract infection, and stone formation. Lee Dong-hun, executive director of GSK Korea CEP (Core Established Products for Patients) BU Head, said, “Duodart, the first 5α-reductase inhibitor and α blocker fixed-dose combination drug in Korea, is designed to help patients with benign prostatic hyperplasia in Korea more conveniently and effectively manage their disease. I will do my best,” he said.
- Policy
- JW Pharma Hemlibra will be reimbursed starting in May
- by Lee, Tak-Sun Apr 25, 2023 05:56am
- JW Pharma's Hemlibra will also be covered for patients with severe non-antibody hemophilia A from May. Previously, this drug was covered only for hemophilia A patients with antibodies. This increase in coverage is expected to greatly contribute to the quality of life of patients with severe non-antibody hemophilia A, especially pediatric patients. According to the industry on the 21st, Hemlibra has been used as a daily prophylaxis to reduce or prevent bleeding frequency in patients with severe hemophilia A (congenital factor VIII deficiency) who do not have factor VIII inhibitors since May. Even if you use it, the salary will be applied. In other words, severe hemophilia A patients without antibodies can receive health insurance benefits when using Hemlibra. In the meantime, non-antibody hemophilia patients have been using intravenous treatment two to three times a week. Hemlibra is expected to be more convenient than existing intravenous treatments because the preventive effect lasts with subcutaneous injections from once a week to once every 4 weeks. In particular, it is analyzed that it will help improve the quality of life of pediatric patients. In the parliamentary audit last year, the rapid payment of Hemlibra for pediatric patients with non-antibody hemophilia was also an issue. According to the 2019 Hemophilia Foundation White Paper, among a total of 1,746 patients with hemophilia A in Korea, 78 were antibody patients and 1589 non-antibody patients were resistant to the existing treatment (factor 8 drug). Among them, severely ill patients accounted for 1259 (72.1%). Hemlibra is a treatment for hemophilia A developed by Chugai, a subsidiary of Roche, in Japan. This time, Hemlibra's drug price will be reduced as reimbursement increases. The 30mg/1mL product is adjusted to 2.28 million won per bottle, 60mg/0.4mL to 4.56 million won, 90mg/0.6mL to 6.84 million won, 0.105g/0.7mL to 7.98 million won, and 0.15g/1mL to 11.4 million won. From May, Chinese pharmaceutical company BeiGene's anti-cancer drug 'Brukinsa 80mg' will be covered. This drug is reimbursed for the treatment of Waldenstrom's macroglobulinemia (WM). Waldenstrom's macroglobulinemia (WM) is a rare blood cancer in which the bone marrow produces large numbers of abnormal white blood cells that crowd out healthy blood cells. The US FDA approved Brukinsa as a treatment for WM in September 2021. In Korea, it is attracting attention as it is the first case in which a Chinese new drug entered the right to benefit. Brukinsa is priced at 34,100 won per capsule. Expenditure cap RSA is applied to this drug.
- Company
- Generic SPC therapies challenge 'Trajenta'
- by Kim, Jin-Gu Apr 25, 2023 05:56am
- Product photo of Trajenta Major generic companies are challenging the unlisted patent of 'Trajenta (linagliptin)', a DPP-4 inhibitor-based diabetes treatment. For 6 months since last September, 10 pharmaceutical companies have successively filed trials on 7 patents. It is believed that the companies are aiming for the release of Trajenta generics and Trajenta+Forxiga (dapagliflozin) combination products, as the product patent expires next year. According to the pharmaceutical industry, Sinil Pharmaceutical, Hutecs Korea Pharmaceutical and Hanlim Pharm recently simultaneously filed a defensive confirmation trial for the scope of rights and invalidation trial on three unlisted patents, on the 24th. The patents are for separate formulation patents that expires in April 2027. Since last September, challenges to unlisted patents of Trajenta have been continuing. In September of last year, Genuone Sciences have first filed for a defensive confirmation trial for the scope of rights against a formulation patent that expires in April 2027. Since then, Korea United Pharm, Korea Biochem Pharm, Sinil Pharmaceutical, Hutecs Korea Pharmaceutical, Hanlim Pharm, etc. have joined the challenge. In last October, Genuone Sciences, Boryung, Mother's Pharmaceutical, Kukje Pharm, and GC Biopharma have filed for invalidation trials against three different use patents of Trajenta, which expires in May 2027. In the last 7 months, 10 generic companies have challenged 7 unlisted patents of Trajenta. The patents are not listed in the Ministry of Food and Drug Safety Patent List. From the generic companies' standpoint, there is no problem in obtaining approval for a generic without challenging the patents. However, the matter becomes different when it comes to releasing an actual product. Administratively, it is possible to release a product at the time of the expiration of the patent, but there is a risk of being involved in a patent infringement lawsuit with the company of the original product. If the original company files for a patent infringement lawsuit as well as an injunction to prevent the release of the general product, the release date of the product may be delayed. This is because if the patent infringement lawsuit is lost, it could lead to a damages suit. It seems that the generic companies are challenging unlisted patents of Trajenta to resolve such uncertainties. If they succeed in avoiding or invalidating the unlisted patents of Trajenta, it could trigger the early release of generics after the product patent of Trajenta expires in June next year. In 2015, generic companies simultaneously challenged the crystalline form patent and product patent of Trajenta. However, they failed to overcome the product patent. The companies plan to release generics in June next year, as the product patent of Trajenta expires. The fact that the patent for Forxiga, an SGLT-2 inhibitor-based diabetes treatment, expired in March also seems to be a reason why generic companies are challenging an all-out attack on the unlisted patents of Trajenta. As reimbursement has recently been applied to DPP-4 inhibitors, SGLT-2 inhibitors and Metformin combination triple therapies, the combination therapy of such ingredients are expected to attract tremendous attention in the prescription drug market. It is expected that the generic companies will be releasing combination products of 'Linagliptin+Dapagliflozin' as the patent for Trajenta expires. Among major DPP-4 inhibitor-based diabetes treatments, the patents for Norvatis's Galvus (Vildagliptin) and Handok's Tenelia (Teneligliptin) have been expired. However, generic companies have been greatly interested in Januvia (Sitagliptin) and Trajenta, as the two were ranking first and second in the prescription drug market among the existing DPP-4 inhibitors. The product patent for Januvia will be expired in September this year. According to UBIST, a pharmaceutical market research institute, the prescription amount of Trajenta last year was KRW 64.2 billion. Trajenta Duo, in which metformin was added to Trajenta, recorded a prescription performance of KRW 68.3 billion.
- Company
- BeiGene’s ‘Brukinsa’ to be prescribed in general hospital
- by Eo, Yun-Ho Apr 25, 2023 05:56am
- Chinese pharmaceutical company BeiGene Korea's first new drug, 'Brukinsa', has been approved to be prescribed in general hospitals. According to sources from related industry, the BTK inhibitor Brukinsa (Zanubrutinib) has passed the Drug Committee of tertiary hospitals such as Samsung Medical Center, SNUH, and Asan Medical Center. As reimbursement is expected to be applied in May, it is believed that prescriptions will be available quite soon after being listed. Brukinsa has been approved in Korea in 2022, as ▲ monotherapy for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and ▲ monotherapy for adults with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy. Among them, reimbursement is for the 'Waldenström's macroglobulinaemia' indication. After approval, only the reimbursement standard for WM was introduced and has been set at the HIRA's Review Committee for Cancer Diseases. In September of the same year, the company tried to add MCL to the list, but the results were not good. Since then, Brukinsa passed the Drug Benefit Evaluation Committee in February of this year and has recently concluded drug price negotiation and is set to be finally listed. Brukinsa is a targeted anticancer medicine that inhibits the survival and proliferation of malignant B cells by blocking the Bruton's tyrosine kinase protein, a signaling molecule that affects the survival and development of B cells. BTK inhibitors approved in Korea include Janssen's Imbruvica (Ibrutinib), AstraZeneca's Calquence (Acalabrutinib), and Ono Pharmaceutical's Velexbru (Tirabrutinib).
- Policy
- Original Concor voluntarily reduced the price
- by Lee, Tak-Sun Apr 25, 2023 05:56am
- Concor (Bisoprolol fumarate), the original β-blocker antihypertensive drug, voluntarily lowered its drug price, gaining recognition and price competitiveness. Many generic drugs are more expensive than original drugs, so marketing activities are expected to be difficult. According to the industry on the 24th, the price of Concor 5mg will go down from next month from 222 won to 200 won. The price of Concor 2.5mg will be reduced from 132 won to 120 won. The company lowered the price itself. Concor is a second-generation β-blocker that has been sold in Korea since 2001 and has established itself as a treatment for hypertension, angina pectoris, and chronic heart failure. In particular, as the awareness of original products increases, there is a big gap with generic products. As of last year, Concor's outpatient prescriptions amounted to 18.6 billion won. Since 2020, Daewoong Pharmaceutical has exclusively sold the drug in Korea. As the company's performance is sound and the market share of generic drugs is low, the market is also showing a skeptical response to the voluntary lowering of the drug price this time. The fact that Elyson's lowest-priced generics continued to increase their market share was a potential cause for concern. Bisoprolol fumarate 5mg has eight products, including Concor and Elyson Conbloc. Previously, Concor and six generics were priced the same at 222 won, and only Conbloc 5mg was listed at 198 won. For Bisoprolol fumarate 2.5mg, Elyson Conbloc 2.5mg was 124 won and Concor tablet 2.5mg was 132 won. With this price cut, Concor narrowed the gap with Conbloc by 2 won in the 5mg product and became 4 won cheaper in the 2.5mg market. Currently, in the generic market, all but Elyson are producing less than 1 billion won a year. On the other hand, Conbloc, which boasts drug price competitiveness, is increasing every year to KRW 3.6 billion last year according to UBIST. Conbloc is drawing an upward trend with 1.1 billion won in 2017, 1.8 billion won in 2018, 2.3 billion won in 2019, 2.9 billion won in 2020, 3.5 billion won in 2021, and 3.6 billion won in 2022. Compared to Concor's performance of 18.6 billion won in 2022, there is still a gap. However, Concor's 2022 performance is down 3% from the previous year. If this trend continues, Conbloc's market share may increase and Concor's market share may decrease. This drug price cut is interpreted as the intention of Concor to gain an absolute advantage in generic competition. It is expected that the six generic companies, which had the same drug price as Concor, could suffer damage. Previously, these six companies only produced less than 1 billion won per year, but it is expected that their market competitiveness will further weaken as the original drug price cut overlaps. There is also a way to lower the price of the drug depending on the original, but in this case, it seems that it will worry about whether to continue the business because it comes back to the cost burden. Elyson, which has put forward a low price, is expected to become a burden on marketing activities as the price becomes similar to the original. It remains to be seen what effect the original drug's voluntary price cut will have on the market.
- Company
- The atopic dermatitis tx market has grown into children
- by Hwang, byoung-woo Apr 24, 2023 05:53am
- Product photos of major atopic treatments Competition in the atopic dermatitis treatment market is intensifying again as new treatments have been made into health insurance benefits one after another. This is because salaries for severe atopic treatments have been expanded from April to children and adolescents. More fierce competition for market share is expected because the demand is high enough to insist on continuously expanding salaries in the clinical field. Experts say that Dupixent and Rinvoq, which directly benefited from the expansion of the salary range, have different characteristics, the choice of clinical sites will also depend on the patient's situation. According to the pharmaceutical industry on the 14th, competition among pharmaceutical companies has been accelerating as the scope of benefits for severe atopic treatments has been expanded from April to children and adolescents. Previously, patients with severe atopic dermatitis in children and adolescents over the age of 6 had a high burden of disease, but limited treatment options that could be used safely in the long run. TCS and Cyclosporine are mainly used to treat atopic dermatitis in children. Patients with moderate-severe atopic dermatitis needed additional systemic treatment because it did not improve with local treatments. Still, there were concerns about local side effects when using even low-grade TCS for a long time in thin skin areas. In addition, in the case of pediatric atopy, it was pointed out that it was difficult to use treatments strongly due to growth and development, so it was not in line with reality to apply for the existing special calculation benefits. "Symptoms such as severe itching caused by atopic dermatitis can have a greater negative impact than adults, such as hindering adolescents' growth and studies," said Woo Sang-wook, chairman of the Korea Atopic Dermatitis Association (KOREA University Ansan Hospital). Dupixent is expected to be most affected by the expansion of the salary range. In the case of Rinvoq, the salary target has increased for teenagers aged 12 or older, while Dupixent has a wider benefit standard for those aged 6 or older. Looking at the new standards for severe atopic patients in children and adolescents, the salary standards for adolescents are the same as those for adults aged 18 or older. The Dupixent benefit standard for children aged 6-11 is relatively low in cases where the ecological severity evaluation index (EASI) is 21 or higher before the start of ▲ Dupixent administration for more than 4 weeks, or cannot be used as a side effect. Chairman Son said, "There will be no major difficulty in using Dupixent because it uses topical treatment for 4 weeks in pediatric atopy and immunotherapy is included in the standard." Then, how will the choice of the clinical site be divided into the severe atopy of adolescents where Dupixent and Rinvoq will face off? Experts predicted that prescriptions would be made considering the method of administration, the speed of effectiveness, and safety according to the patient's condition. Ahn Ji-young, a professor of dermatology at NMC, said, "Since they are children, I think there will be more considerations than adults, such as preferences depending on how they think of injections and the burden of visiting the hospital." Along with this, the part that can be considered is the drug price. This is why Dupixent is expected to cost up to 1.33 million won to 1.74 million won although the patient's burden will be greatly reduced at the time of application. In the case of Rinvoq, it costs 60,300 won based on the premise that a month is 30 days with a drug price of KRW 20,010 per day of 15 mg. If 10% of the calculation special case is applied here, the patient burden is 60,030 won, which costs 72,360 won when converted into a year, so the patient burden is less than Dupixent. "It is true that Rinvoq has a few hundred thousand won less burden on patients compared to Dupixent," said a professor of pediatrics at A University Hospital. "However, I don't think there is a big difference between treatments, and I think which treatments will be more effective for patients will be a priority."
- Company
- Myelofibrosis new drug Inrebic can be prescribed
- by Eo, Yun-Ho Apr 24, 2023 05:52am
- The Myelofibrosis drug Inrebic is now available for prescription in general hospitals. According to related industries, Inrevic, a myelofibrosis treatment drug from BMS Pharmaceuticals, passed the Drug Committee (DC) of general hospitals such as SMC and Seoul St. Mary's Hospital. Inrebic received domestic approval in April of last year as 'treatment for splenomegaly or symptoms related to primary myelofibrosis, polycythemia vera, and myelofibrosis after essential thrombocythemia in adult patients previously treated with Jakavi. After that, he submitted an application for benefits but failed to pass HIRA once in June of last year. After re-applying, it passed both the Cancer Disease Review Committee and the Pharmaceutical Reimbursement Evaluation Committee last month, and the results of the drug price negotiations with The NHIS are expected to be released soon. This drug is a JAK-2 inhibitor and is expected to be different from Jakavi, a JAK1/2 inhibitor. Inrebic is the first to obtain approval for an oral once-a-day drug that greatly reduces the burden of spleen volume and symptoms in patients with myelofibrosis who have not had a history of treatment. Myelofibrosis is a rare blood cancer that affects the bone marrow and interferes with the body's normal production of blood cells. Patients suffer from symptoms such as an enlarged spleen, fatigue, itching, weight loss, night sweats, fever, and bone pain, which affect their quality of life. experience symptoms. Jakavi was the only JAK inhibitor approved for the treatment of myelofibrosis, and there was no alternative for patients who failed treatment. Inrebic is a treatment that appeared 10 years after Jakavi in the myelofibrosis market, where there was no second-line treatment option. Inrebic is currently covered through the Cancer Drug Fund in the UK. In 2021, NICE refused to apply Inrebic to NHS benefits. However, CDF recommends the use of Inrebic within its oncology fund for the treatment of splenomegaly or other symptoms associated with the disease in patients with myelofibrosis who have previously been treated with Jakavi.
- Policy
- Price of Eliquis reduced by 3.5%... Kanarb by 1.7% each
- by Kim, Jung-Ju Apr 24, 2023 05:52am
- Merck's Mavenclad tab. (cladribine), which is used to treat relapsing-remitting multiple sclerosis, has become subject to price cuts under the price-volume agreement and will be sold at a 6.9% lower price starting next month. The price of Boryung’s flagship hypertension drug, Kanarb (fimasartan potassium trihydrate), will be reduced by 1.7% for each dose, and the price of BMS Korea Eliquis will also be reduced by 3.5% for each dose. According to industry sources on the 21st, the Ministry of Health and Welfare is planning to revise the 'Drug Reimbursement List and Reimbursement Ceiling Amount Table' and apply it on the 1st of next month. A total of 6 products will be applied PVA price cuts. One is subject to ‘PVA Type A’ and the other 5 are subject to ‘PVA Type B’ and the subject drugs have been conducting negotiations with the National Health Insurance Service until now. ◆PVA Type A = Price of only 1 drug classified as 'type A' will be reduced after completing negotiations with the government. Among new drugs listed as negotiable after the introduction of the drug price negotiation system, the government applies PVA A type to drugs whose claims amount in the same product category exceeds the expected claims amount by over 30%. By same product category, drugs that have the same company name, route of administration, ingredient, and formulation are classified as drugs of the same product category. The drug subject to ‘Type A’ price reduction is Merck’s Mavenclad Tab. Its price is set to be reduced by 6.9%, and the price cut will be applied starting on the 1st of next month. ◆PVA Type B = Also, 5 drugs that were classified as Type B will receive price discounts this time. The government applies PVA Type B and reduces the price of drugs ▲whose price ceiling had been already adjusted according to Type A, ▲ whose claims amount increased by over 60% from the previous year without undergoing Type A negotiations, or 4 years after receiving Type A negotiations, or ▲ has increased by over 10% but the increased amount exceeds KRW 5 billion and does not fall under PVA Type A. By each item, the price of 60mg and 120mg doses of Boryung’s Kanab Tab. will be reduced by 1.7%, respectively. The price of its 30mg dose product will be reduced by 1.8%. Eliquis's insurance drug prices will fall by 3.5% each for both the 2.5mg and 5mg doses.
